Trial reveals differences in pain-relieving drugs when combined with aspirin

April 16, 2018, Cleveland Clinic
Credit: CC0 Public Domain

A landmark 2016 Cleveland Clinic study of widely used pain-relieving drugs showed that celecoxib (Celebrex) was associated with comparable cardiovascular safety and better gastrointestinal (GI) and kidney safety when compared with either naproxen (Naprosyn) and ibuprofen (Motrin).

A new substudy, published today in the Journal of the American College of Cardiology, analyzed outcomes in PRECISION based on the presence or absence of aspirin use with specific NSAIDs (nonsteroidal anti-inflammatory drugs). The research shows that taking aspirin with lessened its advantage, although it was still associated with fewer GI problems than either of the other drugs and fewer kidney issues than ibuprofen.

The decade-long PRECISION trial - Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen - studied osteoarthritis or patients who required daily prescription use of NSAIDs for pain relief. All participants had pre-existing heart disease or increased risk for developing heart disease.

The researchers reviewed occurrences of major adverse cardiovascular events such as heart attack or stroke, noncardiovascular death, clinically significant GI events, anemia of GI origin or serious renal events. GI problems including ulcers or chronic bleeding are known complications of NSAIDs, and NSAIDs are also known to cause kidney complications.

The substudy followed nearly 24,000 patients with osteoarthritis or rheumatoid arthritis who were taking daily prescription doses of either celecoxib, naproxen or ibuprofen for a minimum of 18 months. Of those patients, 11,000 were also taking aspirin. Adding aspirin diminished some of the safety advantage for celecoxib that was observed in the PRECISION trial - as patients taking both had more of a risk for major adverse events compared to those on just celecoxib alone. However, even with aspirin, celecoxib patients still had slightly less overall adverse outcomes than those taking ibuprofen with aspirin (6 percent vs 7.1 percent). There was not a significant overall difference between celecoxib and naproxen with aspirin. In addition, celecoxib patients had fewer GI problems than ibuprofen (0.9 percent vs. 1.4 percent) or naproxen (1.6 percent) and fewer renal issues than ibuprofen (0.6 percent vs. 1.2 percent).

"NSAIDS are some of the most widely used drugs in the world with more than 100 million prescriptions issued annually in the United States. Past studies have reported conflicting results regarding using NSAIDs together with aspirin, but we know that many patients do combine the medications, so it was vital to understand the risks and differences among the drugs," said Steve Nissen, M.D., chairman of Cardiovascular Medicine at Cleveland Clinic, and the study's principle investigator.

"The outcomes of this study could lead to changes in clinical practice. If a patient is not on aspirin, these results suggest that in many cases, celecoxib may be the NSAID of choice," said Grant Reed, M.D., an interventional cardiology fellow at Cleveland Clinic, and the study's first author. "Our findings underscore how important it is that physicians counsel their patients when starting them on an NSAID and consider the potential effects of use together with ."

The PRECISION trial was initiated following the withdrawal of rofecoxib (Vioxx) - a drug in the same class as celecoxib that worked similarly - from the market in 2004. The FDA mandated a clinical trial to determine if celecoxib shared a similar increased risk of heart-related complications. PRECISION, known as a non-inferiority trial, demonstrated celecoxib is not more risky than the other two drugs, which are older and work in a different way. The primary outcomes of heart attack, stroke or death occurred in 2.3 percent of patients taking celecoxib, 2.5 percent of patients taking naproxen, and 2.7 percent of patients taking ibuprofen. PRECISION also assessed a broader measure of cardiovascular safety - the primary outcome plus hospitalization for unstable angina or coronary revascularization (stenting or bypass) - and showed a 15 percent higher risk for ibuprofen than celecoxib, but this difference was borderline in statistical significance.

The PRECISION trial also assessed GI and renal complications. GI problems including ulcers or chronic bleeding are known complications of NSAIDs. Celecoxib and rofecoxib were introduced in 1999 as a new type of NSAID designed to reduce the risk of GI complications. In the PRECISION trial, the rate of ulcers or GI bleeding was 54 percent higher for ibuprofen, and 41 percent higher for naproxen than celecoxib.

NSAIDs are also known to cause kidney complications and the trial showed a statistically significant 64 percent higher risk of worsening kidney function for compared with celecoxib. Numerically more occurred with naproxen, but the difference was not statistically significant. Death from any cause was approximately 25 percent higher with naproxen than celecoxib, but this difference was borderline in statistical significance.

Osteoarthritis is the most common form of arthritis affecting more than 16 million Americans. Rheumatoid arthritis is a type of chronic arthritis that is an autoimmune disease affecting joints on both sides of the body. Rheumatoid arthritis is 2.5 times more common in women than men and affects more than 1.3 million people in the United States. Patients with rheumatoid arthritis are at an increased risk for heart disease. In the trial, 90 percent of had osteoarthritis and 10 percent had rheumatoid arthritis.

Explore further: Ibuprofen associated with blood pressure rise in arthritis patients at cardiovascular risk

Related Stories

Ibuprofen associated with blood pressure rise in arthritis patients at cardiovascular risk

August 28, 2017
Ibuprofen is associated with increased blood pressure and hypertension compared to celecoxib in patients with osteoarthritis or rheumatoid arthritis and increased risk of cardiovascular disease, according to late-breaking ...

Risk of heart disease associated with NSAIDs

May 8, 2017
Dear Mayo Clinic: Is it true that taking prescription-strength nonsteroidal anti-inflammatory drugs, or NSAIDs, can increase my risk of heart disease? How much is too much, and should I be concerned about regularly taking ...

13-country precision trial looks at cardiovascular effects of anti-inflammatory drug use

November 14, 2016
A 10-year trial involving osteoarthritis and rheumatoid arthritis patients in 13 countries reveals new insights on the cardiovascular safety of widely used nonsteroidal anti-inflammatory drugs and COX-2-specific inhibitors, ...

Do pain medications carry different heart risks?

February 22, 2018
Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across ...

Celebrex may not pose bigger heart risk than similar drugs: study

November 14, 2016
(HealthDay)—Some people taking the pain reliever Celebrex may not have a greater risk for heart problems than those taking other nonsteroidal anti-inflammatory drugs (NSAIDs), a new study says.

Study quells concerns about NSAID safety

August 31, 2015
In older patients with arthritis and no history of cardiovascular disease, chronic use of any non-steroidal anti-inflammatory drug appears safe from a cardiovascular and gastrointestinal stand-point, and regular, non-selective ...

Recommended for you

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Study reveals new link between atrial fibrillation and mutations in heart disease gene

December 11, 2018
Atrial fibrillation (Afib), a heart condition that causes a rapid, irregular heartbeat that increases a person's risk of stroke and heart failure, is fairly common among older adults. However, its early onset form is relatively ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Study: Age, race differences determine risk of stroke in women and men

December 11, 2018
A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, ...

Workplace exposure to pesticides and metals linked to heightened heart disease risk

December 11, 2018
Workplace exposure to metals and pesticides is linked to a heightened risk of heart disease in Hispanic and Latino workers, reveals research published online in the journal Heart.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.